Guangdong Yongshun Biopharmaceutical Co., Ltd. Huashen Group (Information Market Forum) is an authentic animal vaccine manufacturer. In terms of animal vaccines, the "pseudorabies gene deletion vaccine" with an investment of 29.5 million yuan won the national first-class veterinary biological agent new drug certificate and was included in the 200 1 national key scientific and technological innovation project, which pioneered the practical application of animal virus genetic engineering vaccines in China and became a substitute for imported vaccines. The background of the company's largest shareholder is the Medical Research Institute of Chengdu University of Traditional Chinese Medicine, with strong scientific research strength. The preliminary work of the pseudorabies gene deletion vaccine production project is also being actively carried out, and the infrastructure project has been basically completed. The vaccine has a broad market prospect. At present, the domestic market mainly relies on imported vaccines. Veterinary biological agents such as pseudorabies vaccine have passed the GMP certification of the Ministry of Agriculture, and the production approval will be obtained soon.

The company is the first avian influenza vaccine manufacturer approved by the Ministry of Agriculture, with a production capacity of over 654.38+0.3 billion feathers.

Nanjing Meilia is the world's largest producer of animal vaccines, and the good biological products of Ganyuan are also exported to Southeast Asia and other areas with serious epidemics. The company's main products include three parts: poultry vaccines, veterinary vaccines and special vaccines. It is the backbone enterprise with the most complete product variety, the largest production capacity, stable and excellent quality and the first market share in China.

After strict screening by the Ministry of Agriculture, Guangdong Yongshun Bio-pharmaceutical Co., Ltd. became the only special vaccine manufacturer for Streptococcus suis type 2 in China.

Domestic listed companies engaged in veterinary vaccine industry mainly include Zhongmu, Jinyu Group and Zheng Hong Science and Technology. Among the designated production enterprises designated by the Ministry of Agriculture, the approved production capacity of Zhongmu Company is 654.38+0.5 billion feather/year, while that of Inner Mongolia Jinyu Group and Sichuan Jinhua are both 654.38+0.5 billion feather/year. As leading domestic livestock and poultry vaccine enterprises, Zhongmu and Jinyu Group are expected to seize the market opportunities in the avian influenza epidemic, which deserves special attention.